# HotSpot Therapeutics, Inc.

> HotSpot Therapeutics is a Boston-based clinical-stage biopharmaceutical company pioneering a new class of allosteric medicines. Using its proprietary Smart Allostery and SpotFinder platforms, the company systematically identifies 'natural hotspots' - regulatory allosteric pockets the body uses to switch proteins on and off - to drug targets long considered undruggable. Its small-molecule pipeline spans oncology (CBL-B, CBM signalosome/KRAS) and autoimmune disease (IRF5), with its lead CBL-B inhibitor HST-1011 in Phase 1/2 clinical trials.

- **Founded:** 2017
- **Headquarters:** Boston, Massachusetts, United States
- **Founders:** Jonathan Montagu (Co-Founder & CEO), Geraldine Harriman (Co-Founder & Chief Scientific Officer)
- **Team size:** ~61 employees
- **Products:** Smart Allostery platform, SpotFinder, HST-1011 (CBL-B inhibitor), HST-2011 (IRF5 inhibitor), CBM signalosome program
- **Notable:** Raised $210M total across Series A-C to industrialize allosteric drug discovery., Advanced lead CBL-B inhibitor HST-1011 into Phase 1/2 clinical trials., Presented first-in-human Phase 1 data at ESMO Congress 2024 showing increased immune activation.

## Products & services

- **Smart Allostery platform** — Proprietary discovery engine that integrates computation, AI, structural biology and chemistry to identify and drug allosteric 'regulatory hotspots' on proteins.
- **SpotFinder** — Technology to systematically identify and target regulatory hotspots - a family of allosteric sites nature uses to control protein function.
- **HST-1011 (CBL-B inhibitor)** — Lead oncology asset, an oral small-molecule CBL-B inhibitor in a Phase 1/2 study for advanced solid tumors refractory to anti-PD(L)1 therapy.
- **HST-2011 (IRF5 inhibitor)** — Potent, selective small-molecule inhibitor of interferon regulatory factor 5 for autoimmune diseases including lupus, Sjogren's, RA, systemic sclerosis and myositis.
- **CBM signalosome program** — IND-stage program targeting the CARD11-BCL10-MALT1 signalosome for KRAS G12X-driven solid tumors.

## Achievements

- Raised $210M total across Series A-C to industrialize allosteric drug discovery.
- Advanced lead CBL-B inhibitor HST-1011 into Phase 1/2 clinical trials.
- Presented first-in-human Phase 1 data at ESMO Congress 2024 showing increased immune activation.
- Presented preclinical IRF5 program data at FOCIS 2025 with reduced joint swelling in arthritis models.
- Built the first platform to systematically identify and target regulatory hotspots (SpotFinder / Smart Allostery).

## Latest updates

- **2025-06** — Presented preclinical data from its small-molecule IRF5 program at FOCIS 2025, showing reduced interferon response genes and joint swelling in arthritis models.
- **2024-11** — Presented additional Phase 1 biomarker data for HST-1011 at the SITC Annual Meeting.
- **2024-09** — Presented first-in-human Phase 1 clinical data on CBL-B inhibitor HST-1011 at ESMO Congress 2024.
- **2021-11** — Closed an oversubscribed $100M Series C to advance its platform into the clinic.

## Links

- Website: https://www.hotspotthera.com
- LinkedIn: https://www.linkedin.com/company/hotspot-therapeutics
- Twitter/X: https://twitter.com/hotspotthera

---

Profile page: https://yespress.io/hotspot-therapeutics-inc
Published by YesPress — https://yespress.io
Last updated: 2026-06-14